Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 6 Researches
7.8
USERS' SCORE
Good
Based on 2 Reviews
8.5
Supplement Facts
Serving Size: 1 Tablet
Amount Per Serving
%DV
Folate
667 mcg DFE (400 mcg Folic Acid)
167%
Calcium (as Calcium Carbonate)
100 mg
8%
Top Medical Research Studies
9
Folic acid-modified vesicles tackle RA
This study presents an innovative approach to tackling rheumatoid arthritis (RA) using folic acid-modified ginger-derived extracellular vesicles (FA-GDEVs). We explored how these tiny vesicles, enriched with bioactive compounds from ginger, can be directed toward inflamed joints by utilizing folic acid to target specific immune cells.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Read More
9
We observed that rheumatoid arthritis (RA) can vary greatly in how patients respond to methotrexate (MTX), a common treatment. Our study focused on understanding how certain genetic variations in the folate pathway could influence this response.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
Read More
8
Folic acid aids RA treatment adherence
We examined the impact of folic acid on the treatment of rheumatoid arthritis (RA) in elderly patients who are commonly prescribed methotrexate (MTX). In a retrospective cohort study involving 198 patients, it became evident that while MTX is a primary treatment option, it often leads to withdrawal due to adverse events (AEs).
The study revealed that the incidence of discontinuing MTX because of AEs was significant over time, with 51.7% of patients stopping treatment by the 15-year mark. Notably, we found that a higher dose of MTX, especially doses of 15 mg per week or more, increased the risk of withdrawal. In contrast, the use of folic acid appeared to protect against this risk, showing a lower hazard for patients who were taking it.
This highlights that while MTX is effective for managing RA, careful consideration of dosage, alongside folic acid supplementation, can play a crucial role in maintaining treatment adherence among elderly patients. Enhancing patient care involves balancing these factors to minimize the potential for adverse reactions.
The study revealed that the incidence of discontinuing MTX because of AEs was significant over time, with 51.7% of patients stopping treatment by the 15-year mark. Notably, we found that a higher dose of MTX, especially doses of 15 mg per week or more, increased the risk of withdrawal. In contrast, the use of folic acid appeared to protect against this risk, showing a lower hazard for patients who were taking it.
This highlights that while MTX is effective for managing RA, careful consideration of dosage, alongside folic acid supplementation, can play a crucial role in maintaining treatment adherence among elderly patients. Enhancing patient care involves balancing these factors to minimize the potential for adverse reactions.
Read More
Most Useful Reviews
8.8
Reliable vitamins
The price and quality are fantastic. Great value for money! I find that taking this for a week aids in the treatment of my rheumatoid arthritis. I trust the vitamins from this company, as they offer better price and composition compared to those from pharmacies.
Read More
8
Helpful supplements
Superb! I take folic acid to support my liver and counteract the harmful effects of methotrexate (I have rheumatoid arthritis). The small tablets are easy to swallow.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 6 Researches
7.8
- All Researches
9
Folic acid-modified vesicles tackle RA
This study presents an innovative approach to tackling rheumatoid arthritis (RA) using folic acid-modified ginger-derived extracellular vesicles (FA-GDEVs). We explored how these tiny vesicles, enriched with bioactive compounds from ginger, can be directed toward inflamed joints by utilizing folic acid to target specific immune cells.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Read More
9
We explored a new approach to treat rheumatoid arthritis by utilizing a combination of methotrexate and RELA siRNA delivered through folate-liposomes. This innovative method aims to target specific immune cells, namely macrophages, to alter their behavior and reduce inflammation indirectly.
In our investigations, we observed that this treatment significantly diminished inflammation in joint tissues and enhanced mobility in rat models of collagen-induced arthritis. By focusing on the NF-κB pathway, we found that the therapy effectively lowered levels of inflammatory markers like rheumatoid factor and C-reactive protein.
However, it’s worth noting that while folate plays an important role in this innovative delivery system, it’s challenging to pinpoint how much of the treatment's success can be attributed solely to folate itself. Overall, this study highlights exciting possibilities in managing rheumatoid arthritis while addressing the need for improved drug delivery and sustained therapeutic effects.
In our investigations, we observed that this treatment significantly diminished inflammation in joint tissues and enhanced mobility in rat models of collagen-induced arthritis. By focusing on the NF-κB pathway, we found that the therapy effectively lowered levels of inflammatory markers like rheumatoid factor and C-reactive protein.
However, it’s worth noting that while folate plays an important role in this innovative delivery system, it’s challenging to pinpoint how much of the treatment's success can be attributed solely to folate itself. Overall, this study highlights exciting possibilities in managing rheumatoid arthritis while addressing the need for improved drug delivery and sustained therapeutic effects.
Read More
9
We observed that rheumatoid arthritis (RA) can vary greatly in how patients respond to methotrexate (MTX), a common treatment. Our study focused on understanding how certain genetic variations in the folate pathway could influence this response.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
Read More
8
Folic acid aids RA treatment adherence
We examined the impact of folic acid on the treatment of rheumatoid arthritis (RA) in elderly patients who are commonly prescribed methotrexate (MTX). In a retrospective cohort study involving 198 patients, it became evident that while MTX is a primary treatment option, it often leads to withdrawal due to adverse events (AEs).
The study revealed that the incidence of discontinuing MTX because of AEs was significant over time, with 51.7% of patients stopping treatment by the 15-year mark. Notably, we found that a higher dose of MTX, especially doses of 15 mg per week or more, increased the risk of withdrawal. In contrast, the use of folic acid appeared to protect against this risk, showing a lower hazard for patients who were taking it.
This highlights that while MTX is effective for managing RA, careful consideration of dosage, alongside folic acid supplementation, can play a crucial role in maintaining treatment adherence among elderly patients. Enhancing patient care involves balancing these factors to minimize the potential for adverse reactions.
The study revealed that the incidence of discontinuing MTX because of AEs was significant over time, with 51.7% of patients stopping treatment by the 15-year mark. Notably, we found that a higher dose of MTX, especially doses of 15 mg per week or more, increased the risk of withdrawal. In contrast, the use of folic acid appeared to protect against this risk, showing a lower hazard for patients who were taking it.
This highlights that while MTX is effective for managing RA, careful consideration of dosage, alongside folic acid supplementation, can play a crucial role in maintaining treatment adherence among elderly patients. Enhancing patient care involves balancing these factors to minimize the potential for adverse reactions.
Read More
8
We developed a unique treatment approach for rheumatoid arthritis (RA) that focuses on targeting inflammatory macrophages with folate-conjugated nanoparticles. These nanoparticles encapsulated Leflunomide (LEF), an immunomodulatory drug commonly used in RA treatment, to enhance its delivery directly to inflamed joints.
By using chitosan and chondroitin sulfate as the base for our nanoparticles, we aimed to leverage their natural anti-inflammatory properties while also incorporating folate to improve targeting. In our study, we observed that these folate-decorated nanoparticles not only successfully delivered LEF but also reduced inflammatory markers more effectively than traditional delivery methods.
Importantly, our results indicated that these nanoparticles preferentially accumulated in inflamed joints when compared to free LEF, showing promise for improved efficacy and reduced side effects. While the study involves multiple components, including polymers and the immunomodulatory agent, the focus on folate's role in targeting macrophages stands out as a significant approach to enhancing RA treatment.
By using chitosan and chondroitin sulfate as the base for our nanoparticles, we aimed to leverage their natural anti-inflammatory properties while also incorporating folate to improve targeting. In our study, we observed that these folate-decorated nanoparticles not only successfully delivered LEF but also reduced inflammatory markers more effectively than traditional delivery methods.
Importantly, our results indicated that these nanoparticles preferentially accumulated in inflamed joints when compared to free LEF, showing promise for improved efficacy and reduced side effects. While the study involves multiple components, including polymers and the immunomodulatory agent, the focus on folate's role in targeting macrophages stands out as a significant approach to enhancing RA treatment.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Reliable vitamins
The price and quality are fantastic. Great value for money! I find that taking this for a week aids in the treatment of my rheumatoid arthritis. I trust the vitamins from this company, as they offer better price and composition compared to those from pharmacies.
Read More
8
Helpful supplements
Superb! I take folic acid to support my liver and counteract the harmful effects of methotrexate (I have rheumatoid arthritis). The small tablets are easy to swallow.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Han R, Zhou D, Ji N, Yin Z, Wang J, et al. Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway. J Nanobiotechnology. 2025;23:41. doi:10.1186/s12951-025-03096-5
- Nasra S, Bhatia D, Kumar A. Targeted Macrophage Re-Programming: Synergistic Therapy With Methotrexate and RELA siRNA Folate-Liposome in RAW264.7 Cells and Arthritic Rats. Adv Healthc Mater. 2024;13:e2400679. doi:10.1002/adhm.202400679
- Avalos-Salgado FA, Gonzalez-Lopez L, Gonzalez-Vazquez S, Ponce-Guarneros JM, Santiago-Garcia AP, et al. Risk Factors Associated with Adverse Events Leading to Methotrexate Withdrawal in Elderly Rheumatoid Arthritis Patients: A Retrospective Cohort Study. J Clin Med. 2024;13. doi:10.3390/jcm13071863
- Patel AV, Morgan SL, Green R, Danila MI, Merriman TR, et al. Vitamin B12 status and hyperhomocysteinemia in patients with Rheumatoid arthritis treated with methotrexate and folic acid. Am J Med Sci. 2024;368:33. doi:10.1016/j.amjms.2024.03.020
- Nomair AM, Abdelati A, Dwedar FI, Elnemr R, Kamel YN, et al. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clin Rheumatol. 2024;43:971. doi:10.1007/s10067-024-06892-w
- Siddiqui B, Ur Rehman A, Gul R, Chaudhery I, Shah KU, et al. Folate decorated chitosan-chondroitin sulfate nanoparticles loaded hydrogel for targeting macrophages against rheumatoid arthritis. Carbohydr Polym. 2024;327:121683. doi:10.1016/j.carbpol.2023.121683
